Key Takeaways
- Volume growth returns, broad-based: After a long absence, volume growth came back at both industry and GSK levels, with all four businesses (general medicines, paediatric vaccines, specialty respiratory, oncology) delivering strong growth.
- Innovation portfolio doubles to 7% of revenue: The specialty/innovation contribution more than doubled YoY and now drives a quarter of overall growth, led by oncology treating ~300 patients in one of its best quarters.
- Gross margin squeezed by oil and rupee: A ~120 bps gross margin decline from rupee appreciation and oil-linked input costs was offset by operating leverage, holding EBITDA margins at 34%.
- Blenrep launch and Hibsago approval mark pipeline delivery: Blenrep enters hemato-oncology in Q3, while Hibsago received US, Japan and Canada approvals as the first potential functional cure for chronic hepatitis B.
- What to watch next quarter: The Blenrep launch execution, whether oil-linked input cost pressure stabilizes, and the trajectory of underlying 12–13% growth as low-base effects fade.
Top-Line Performance & Underlying Growth
- Volume-led growth: Growth was a good blend of price, new introductions and volumes, with underlying Gen Meds volume at a healthy 5–7%, which management views as the closest linkage to prescriptions generated.
- Broad-based across all four businesses: General medicines, paediatric vaccines, specialty respiratory and oncology all delivered strong robust growth; flagship brands in general medicines all exceeded 100% evolution index and added market share.
- Low-base effect quantified: The prior-year same quarter had a sizeable impact from a CMO fire at a key production site and GST 2.0; stripping that out, repeatable underlying growth is 12–13%, with tailwinds contributing an incremental 6–7% delta.
- Calpol recovery substantially complete: Supply disruption from a supplier-end issue has been substantially recovered; the Evolution Index ahead of 112% indicates growth significantly faster than market, with underlying growth in excess of 30–35% for Q2.
- Established products volume: Mid to high single-digit volume growth on the established products business, which management views as the cash engine to protect.
- H2 outlook: Expectation that underlying business health should flow into the second half; the aspiration and continued objective is to deliver double-digit growth.
Bhushan Akshikar: "I think our priorities remain firmly anchored around the three priorities that we have set for ourselves as a global biopharma corporation. The first one being relentless pursuit of the top-line growth. ... And then bolting on the second priority, which is really accelerating all the new launches. We have an extensive array of launches coming up in the next 24 to 36 months. ... And third, anything that comes in the way of these two priorities, you know, hacking those inefficiencies and simplifying the ways of working."
Innovation & Specialty Portfolio
- Innovation contribution more than doubled: The portfolio moved from ~3% to 7% of revenues YoY and now contributes a quarter of overall growth.
- Oncology had one of its best quarters: Nucala, Jemperli and Zejula all created new breakthroughs; oncology impacted ~300 patients, exactly a year after launching Zejula for ovarian and Jemperli for endometrial second-line cancers.
- Oncology team built from scratch: Twelve months ago there was no oncology business; today a team of ~50 people covers solid tumors and hematological malignancies, completely separate from established business reps.
- Blenrep launch in Q3 FY27: Enters the hemato-oncology space with an ADC in multiple myeloma, approved for second-line use; adds to the oncology portfolio.
- Hibsago (Bepirovirsen) regulatory progress: Received US FDA approval, Japanese approval and Canadian approval this week; the first potential functional cure for chronic hepatitis B; India launch hoped for in the coming 12 months, with applications being made to Indian regulators.
- Specialty sales model to replicate: The nimble, small-team model (30–50 people) built for oncology will be replicated for each specialty business unit as value unlocks in the coming 12 months.
Ronojit Biswas: "We're very excited about, our launch of Blenrep, which is going to happen in the December quarter. This will take us into this adds to our oncology portfolio. It takes us into the hemato-oncology space with, you know, with an ADC in multiple myeloma."
Vaccines
- Paediatric vaccines held leadership: Maintained leadership position in the self-pay private market and gained market share in a few flagship brands, despite global supply challenges that were resolved before quarter close.
- Shingrix doubled sales YoY: Adult vaccines growth driven by an increase in the number of prescribers and a pivot to cardiovascular linkage data, with data establishing a bidirectional link between shingles prevention and cardiovascular events.
Margins & Cost Structure
- Gross margin erosion of ~120 bps: Driven by rupee appreciation and oil-linked inflation on raw materials, APIs and packaging material; procurement prices are significantly oil-price linked.
- EBITDA margin maintained at 34%: The adverse gross margin impact was offset by a better spend ratio that improved ~1 percentage point via operating leverage.
- Input cost pressure expected to persist: The geopolitical situation driving oil-linked input costs is expected to have an impact for a few quarters until oil prices stabilize.
- Cost of goods levers: Management will continue to take measures to improve cost of goods, using levers such as competitive price increases as done in the past.
- PAT one-off: ₹42 crores interest on an income tax refund boosted PAT; underlying PAT growth was ~21%, in line with sales.
- Margin philosophy: EBITDA is an outcome, not the primary target; the priority is top-line growth in a balanced way while maintaining current profitability levels.
Ronojit Biswas: "What we are also seeing is that procurement prices of, several key input materials, APIs, packaging material, these are all oil price, these are all kind of significantly oil price linked. So, we expect the geopolitical situation to have an impact for a few quarters until the oil prices stabilize."
Strategic Ambition: The 2x Plan
- Aspiration to double the business to ~INR 8,000 crores: The ambition remains undiluted, with internal modelling targeting this by 2031.
- Growth composition: Three-fifths of the growth to INR 8,000 crores is expected from established products organically at high single-digit growth; two-fifths from the new launches pipeline.
- Blended growth rate: Aspiration for 12–13% blended growth over the next five-year period.
- Base business realism: Management does not expect established Gen Meds and paediatric vaccines to grow 15–20% over the next three to five years; a realistic expectation is high single-digit growth.
- Portfolio transformation on track: The transformation to an innovation/specialty business remains on track and is being done profitably.
Management: "It's not about an either-or, it's an and strategy for us in India."
Regulatory & Pricing Environment
- Government of India oncology pricing order: A trade margin rationalization exercise capped margins at 30%; GSK states it was always operating within that band, so no impact is expected on existing business or products launching in the coming two quarters of this financial year.
- Q4 indications: Management is pursuing more indications; the question is whether approvals come in the right time.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Blenrep launch | Enter hemato-oncology space with ADC in multiple myeloma | Q3 FY27 (December quarter) |
| Hibsago India launch | Apply for Indian regulatory approvals for chronic hepatitis B functional cure | Coming 12 months |
| Input cost pressure | Oil-linked procurement cost headwinds to persist | A few quarters, until oil prices stabilize |
| Double the business | Reach ~INR 8,000 crores revenue | By 2031 |
| Blended growth rate | 12–13% blended growth over the next five years | Five-year period |
| Established products growth | High single-digit growth for Gen Meds and paediatric vaccines | Next 3–5 years |
| Specialty sales model | Replicate nimble 30–50 person team model for each new specialty unit | Coming 12 months |
| H2 growth | Deliver double-digit growth | Second half of FY27 |
| Margin profile | Maintain current profitability levels while prioritizing top-line growth | Ongoing |
| Oncology pricing impact | No impact from trade margin rationalization on existing or near-term launches | Coming two quarters of FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹1,180 cr, +21% YoY; highest quarterly sales recorded |
| Underlying revenue growth | 12–13%, excluding low base effect from prior-year CMO fire and GST 2.0 |
| EBITDA | ₹400 cr, +20% YoY |
| EBITDA margin | 34%, maintained; gross margin erosion of ~120 bps offset by ~1 ppt improvement in spend ratio |
| Underlying EBITDA growth | ~13%, stripping tailwinds |
| Profit after tax | +33% YoY; includes one-off income tax refund interest of ~₹42 cr |
| Underlying PAT growth | ~21%, in line with sales growth, excluding one-off |
| Earnings per share | ₹19.76, +32% YoY |
| Cash on balance sheet | ₹2,200 cr, zero debt |
| Cash conversion ratio | 98% |
| H1 FY27 revenue growth | 18% |
| H1 FY27 EBITDA growth | 18% |
| H1 FY27 PAT growth | 29% |
| Innovation portfolio revenue share | 7% of overall revenues, up from ~3% in Q2 FY26 |
| Innovation portfolio growth contribution | ~25% of overall growth |
| Shingrix sales growth | Doubled vs Q2 FY26 |
| Oncology patient impact | ~300 patients treated quarterly with Zejula and Jemperli |
| General medicines volume growth | 5–7%, mid to high single-digit |
| Calpol underlying growth | 30–35% for Q2; Evolution Index ahead of 112% |
| Gross margin erosion | ~120 bps, driven by rupee appreciation and oil-linked input cost inflation |
| Industry market growth (IQVIA) | ~14–14.5% overall; chronic +17%, acute +13% |
| Anti-infectives segment growth | 7.1%, roughly half the industry rate |
| Revenue aspiration | ~₹8,000 cr by 2031, roughly double FY26 levels; ~3/5 from established portfolio, ~2/5 from new launches |
| Blended growth rate aspiration | 12–13% over next five years |
| Oncology team size | ~50 people across solid tumors and hematological malignancies |
| Clinical trials in India | 30+ pivotal Phase 3A/3B global trials, up from 10–12 four years ago |
| Big brands in portfolio | 11–12 assets deemed big by IQVIA (>₹100–150 cr); 4–5 in top 20 |
| Specialty brand potential | ₹300–400 cr individually per brand |